Corcept Therapeutics Incorporated
CORT
Rank in Stocks
#1765
Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo... Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.
Share Price
$112.35
Market Cap
$12.14B
Change (1 day)
1.99%
Change (1 year)
42.77%
Country
US
Trade Corcept Therapeutics Incorporated (CORT)
Category
Healthcare
Number of shares outstanding for Corcept Therapeutics Incorporated (CORT)
Number of shares outstanding as of June 2026: 105.38M
According to Corcept Therapeutics Incorporated latest financial reports and stock price the company's current number of shares outstanding is 105.38M. At the end of December 2023 the company had 103.56M shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for Corcept Therapeutics Incorporated (CORT) from 2001 to 2026
Shares Outstanding at the end of each year
| Year | Shares Outstanding | Change |
|---|---|---|
| 2026 (TTM) | 105.38M | 2.08% |
| 2024 | 103.23M | -0.32% |
| 2023 | 103.56M | -3.02% |
| 2022 | 106.79M | -7.67% |
| 2021 | 115.65M | 0.21% |
| 2020 | 115.41M | 0.93% |
| 2019 | 114.35M | -9.02% |
| 2018 | 125.68M | 10.71% |
| 2017 | 113.53M | 2.68% |
| 2016 | 110.57M | 3.53% |
| 2015 | 106.80M | 5.77% |
| 2014 | 100.98M | 1.16% |
| 2013 | 99.82M | 7.31% |
| 2012 | 93.02M | 11.65% |
| 2011 | 83.31M | 21.91% |
| 2010 | 68.34M | 30.31% |
| 2009 | 52.44M | 12.25% |
| 2008 | 46.72M | 36.41% |
| 2007 | 34.25M | 49.95% |
| 2006 | 22.84M | 1.03% |
| 2005 | 22.61M | 22.60% |
| 2004 | 18.44M | 113.17% |
| 2003 | 8.65M | 28.73% |
| 2002 | 6.72M | 25.00% |
| 2001 | 5.38M | 0.00% |
Shares Outstanding for similar companies or competitors
| Company | Shares Outstanding | Difference | Country |
|---|---|---|---|
| 445.06M | 322.35% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| 18.05B | 17,027.57% |
HK
|
